Transforming Care Through Next Generation Therapies in Retinal Diseases to Lower Burden and Improve Outcomes
An Expansion of Vision RELIEF: No Eyes Left Behind Initiative

FACULTY PRESENTER

Nimesh A. Patel, MD
Director of Pediatric Retina, Associate Fellowship Director, Mass Eye and Ear/Mass General Hospital
Director of Pediatric Retina Surgery, Boston Children’s Hospital
Assistant Professor of Ophthalmology, Harvard Medical School
Boston, Massachusetts

PROGRAM OVERVIEW

This five-episode podcast series is designed to help clinicians recognize and address the unique challenges of optimizing anti-VEGF treatment protocols for ocular conditions, including retinopathy of prematurity, diabetic retinopathy, macular edema, retinal vein occlusion, and neovascular age-related macular degeneration. Join leading retina specialists and ophthalmologists as they discuss critical challenges in retinal disease management, such as overcoming treatment barriers, tailoring individualized therapy approaches, and selecting appropriate patients.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate treatment options, including anti-VEGF therapy, to develop an individualized management plan for patients with ROP

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Nicolas Applyrs Jr, DO, MS, MPH, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: September 05, 2025
EXPIRATION DATE: September 05, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

FACULTY PRESENTER

Judy E. Kim, MD, FARVO, FASRS
Jean and Tom Walter Distinguished Chair in Ophthalmology, in honor of James P. McCulley, MD
Professor of Ophthalmology, Vitreoretinal Diseases and Surgery
Vice-Chair of Education
Medical Director of Clinical Research
University of Texas Southwestern Medical Center
Dallas, Texas

PROGRAM OVERVIEW

This five-episode podcast series is designed to help clinicians recognize and address the unique challenges of optimizing anti-VEGF treatment protocols for ocular conditions, including retinopathy of prematurity, diabetic retinopathy, macular edema, retinal vein occlusion, and neovascular age-related macular degeneration. Join leading retina specialists and ophthalmologists as they discuss critical challenges in retinal disease management, such as overcoming treatment barriers, tailoring individualized therapy approaches, and selecting appropriate patients.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate the latest evidence with second-generation anti-VEGF agents for DR as well as how their efficacy, safety, and durability address current barriers to care and reduces treatment burden
• Design individualized treatment strategies that incorporate patient factors and current real-world and clinical trial data on efficacy and safety of second-generation agents to minimize treatment burden and optimize visual outcomes for patients with DR

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: September 26, 2025
EXPIRATION DATE: September 26, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

FACULTY PRESENTER

Srinivas R. Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California-Los Angeles
Pasadena, California

PROGRAM OVERVIEW

This five-episode podcast series is designed to help clinicians recognize and address the unique challenges of optimizing anti-VEGF treatment protocols for ocular conditions, including retinopathy of prematurity, diabetic retinopathy, macular edema, retinal vein occlusion, and neovascular age-related macular degeneration. Join leading retina specialists and ophthalmologists as they discuss critical challenges in retinal disease management, such as overcoming treatment barriers, tailoring individualized therapy approaches, and selecting appropriate patients.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Recognize clinical trial data on efficacy and safety of approved and investigative second-generation agents for RVO
• Incorporate findings from studies with second-generation anti-VEGF agents for RVO to develop evidence-based treatment strategies

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: October 24, 2025
EXPIRATION DATE: October 24, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

FACULTY PRESENTER

Priya Vakharia, MD
Retina Vitreous Associates of Florida
Collaborative Assistant Professor
University of South Florida Morsani College of Medicine
St. Petersburg, Florida

PROGRAM OVERVIEW

This five-episode podcast series is designed to help clinicians recognize and address the unique challenges of optimizing anti-VEGF treatment protocols for ocular conditions, including retinopathy of prematurity, diabetic retinopathy, macular edema, retinal vein occlusion, and neovascular age-related macular degeneration. Join leading retina specialists and ophthalmologists as they discuss critical challenges in retinal disease management, such as overcoming treatment barriers, tailoring individualized therapy approaches, and selecting appropriate patients.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate the latest evidence with second-generation anti-VEGF agents for nAMD, as well as how their efficacy, safety, and durability address current barriers to care and reduces treatment burden
• Design individualized treatment strategies that incorporate patient factors and current real-world and clinical trial data on efficacy and safety of second-generation agents to minimize treatment burden and optimize visual outcomes for patients with nAMD

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: November 20, 2025
EXPIRATION DATE: November 20, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

FACULTY PRESENTER

David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, Florida

PROGRAM OVERVIEW

This five-episode podcast series is designed to help clinicians recognize and address the unique challenges of optimizing anti-VEGF treatment protocols for ocular conditions, including retinopathy of prematurity, diabetic retinopathy, macular edema, retinal vein occlusion, and neovascular age-related macular degeneration. Join leading retina specialists and ophthalmologists as they discuss critical challenges in retinal disease management, such as overcoming treatment barriers, tailoring individualized therapy approaches, and selecting appropriate patients.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate the latest evidence with second-generation anti-VEGF agents for DME, as well as how their efficacy, safety, and durability address current barriers to care and reduces treatment burden
• Design individualized treatment strategies that incorporate patient factors and current real-world and clinical trial data on efficacy and safety of second-generation agents to minimize treatment burden and optimize visual outcomes for patients with DME

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: December 10, 2025
EXPIRATION DATE: December 10, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

PATIENT

Barbara Ryan

PROGRAM OVERVIEW

This podcast features the story of Barbara, a patient living with diabetic macular edema (DME) who faces significant challenges in maintaining regular appointments, in addition to navigating other health conditions. Barbara shares her experience and her emotional treatment journey for DME, and her story highlights the role of next-generation anti-VEGF agents in mitigating the treatment burden and supporting continuity of care. The discussion offers insights that may assist clinicians in recognizing patient-specific barriers and individualizing therapy accordingly for patients with DME.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate the latest evidence with second-generation anti-VEGF agents for DME, as well as how their efficacy, safety, and durability address current barriers to care and reduces treatment burden

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Shpetim Karandrea, PhD, Medical Director of Med Learning Group, has nothing to disclose.
• Zoe Bloodgood, Medical Education Content Engineer of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: January 30, 2026
EXPIRATION DATE: January 30, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

PATIENT

Dita Domonkos

PROGRAM OVERVIEW

This podcast examines the clinical and real-world implications of treatment burden in neovascular age-related macular degeneration (nAMD), as well as the role of next-generation anti-VEGF agents in reducing this burden and optimizing visual outcomes. Through a discussion with Dita—an nAMD patient transitioned to a next-generation therapy—the episode highlights practical insights into treatment experience, adherence challenges, and patient-centered considerations that can support clinicians in individualizing nAMD management.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists involved in the management of patients with retinal disease.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Evaluate the latest evidence with second-generation anti-VEGF agents for nAMD, as well as how their efficacy, safety, and durability address current barriers to care and reduces treatment burden

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Shpetim Karandrea, PhD, Medical Director of Med Learning Group, has nothing to disclose.
• Zoe Bloodgood, Medical Education Content Engineer of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Please listen to the podcast below:

RELEASED DATE: January 30, 2026
EXPIRATION DATE: January 30, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.